• Users Online: 80
  • Print this page
  • Email this page

    Article Cited by others


Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab

Chiu Tai-Siang, Tsai Tsen-Fang

Year : 2019| Volume: 37| Issue : 3 | Page no: 129-133

   This article has been cited by
1 Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
Cheng-Ying Chiang,Tsen-Fang Tsai
Dermatology and Therapy. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment
T.-F. Tsai
British Journal of Dermatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study
K. Reich,A. Körber,U. Mrowietz,M. Sticherling,C. Sieder,J. Früh,T. Bachhuber
British Journal of Dermatology. 2020;
[Pubmed]  [Google Scholar] [DOI]


Read this article